Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis
Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis. // Clinical Genitourinary Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1558767326001576?dgcid=rss_sd_all
Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis. Clinical Genitourinary Cancer. https://www.sciencedirect.com/science/article/pii/S1558767326001576?dgcid=rss_sd_all
“Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis.” Clinical Genitourinary Cancer.
@article{article40903,
title = {Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis},
journal = {Clinical Genitourinary Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1558767326001576?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...